Apellis Pharmaceuticals Inc
NASDAQ:APLS

Watchlist Manager
Apellis Pharmaceuticals Inc Logo
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Watchlist
Price: 19.53 USD 1.67% Market Closed
Market Cap: 2.5B USD

Apellis Pharmaceuticals Inc
Investor Relations

In the realm of biotechnology, Apellis Pharmaceuticals Inc. has carved out a niche by pioneering therapies that target the complement system, an integral part of the immune response. Founded in 2009, the company quickly honed in on the inhibition of C3, a protein central to the activation of the complement cascade, which can drive various diseases when dysregulated. Through its proprietary platform, Apellis has developed novel therapeutic candidates that aim to modulate the immune system from an entirely fresh angle. The company focuses on addressing serious medical conditions that currently have limited treatment options, such as age-related macular degeneration (AMD) and paroxysmal nocturnal hemoglobinuria (PNH), by employing targeted therapies to reduce inflammation and improve patient outcomes.

Apellis’s business strategy revolves around a model that not only aims to bring innovative treatments to market but also to establish partnerships that broaden the reach of its technology. The company's flagship drug, Empaveli, received FDA approval for PNH in 2021 and underscores its potential to capture larger market segments within rare disease treatment areas. By investing heavily in research and development, Apellis seeks to expand its pipeline while also collaborating with other firms to enhance its capabilities and share the risks and rewards associated with drug development. Revenue is generated primarily through sales of its approved therapies, as well as milestone payments and royalties from partnerships, setting Apellis on a path poised for growth if it continues to advance its clinical programs successfully.

Show more
Loading

Earnings Calls

2025 Q1
May 6, 2025
Show Transcript
Previous
Next
RioCan's resilient performance amid HBC challenges highlights growth potential.
2025 Q1
May 6, 2025

In Q1 2025, RioCan reported a 9% increase in FFO per unit to $0.49, driven by robust same-property NOI growth of 3.6%. Despite macroeconomic uncertainties and Hudson's Bay Company’s CCAA filing impacting operations, RioCan's committed occupancy remained at 98%. The company revised its FFO guidance to $1.85-$1.88 per unit. Notably, RioCan's condo operations generated $22 million in gains, largely influenced by a favorable $11 million cost contingency release. Proceeds from asset sales, totaling $241 million, are expected to enhance liquidity, supporting both debt repayment and unit repurchases at a compelling 11% FFO yield.

Show Full Analysis

Management

Dr. Cedric Francois M.D., Ph.D.
Co-Founder, President, CEO & Director
No Bio Available
Mr. Alec Machiels J.D., MBA
Co-Founder & Director
No Bio Available
Mr. Timothy E. Sullivan
CFO & Treasurer
No Bio Available
Mr. David O. Watson Esq., J.D.
General Counsel
No Bio Available
Dr. Caroline R. Baumal M.D.
Chief Medical Officer
No Bio Available
Dr. Pascal Deschatelets Ph.D.
Co-Founder & Chief Scientific Officer
No Bio Available
Mr. James G. Chopas CPA
VP, Corporate Controller & Chief Accounting Officer
No Bio Available
Ms. Meredith Kaya
Senior Vice President, Investor Relations & Strategic Finance
No Bio Available
Ms. Karen Lewis
Chief People Officer
No Bio Available
Prof. Peter Hillmen M.D., Ph.D.
Head of Hematology Engagement & Member of PNH Scientific Advisory Board
No Bio Available

Contacts

Address
MASSACHUSETTS
Waltham
100 Fifth Avenue
Contacts
+16179775700.0
apellis.com